Advertisement

Pharmaceutisch Weekblad

, Volume 14, Issue 4, pp 221–223 | Cite as

Future developments in the pharmacotherapy of lung disease

  • A. Van der Kuy
Drugs in the Pipeline
  • 16 Downloads

Abstract

Future advances in the pharmacotherapy of lung disease will occur mainly in the treatment of asthma, and will include the development of new long-actingβ2-agonists, long-acting parasympatholytics, phosphodiesterase inhibitors, corticosteroids with fewer systemic side-effects, and other antiinflammatory drugs. Free radicals play an important role in most lung diseases, including asthma, emphysema, fibrosis, and adult respiratory distress syndrome. The search for free radical scavengers is now in progress. Replacement therapy with α1-antitrypsin and surfactant is now possible. Progress in this area stems principally from a better understanding of the pathogenesis of lung disease.

Keywords

β2-Agonists, long-acting α1-Antitrypsin, deficiency Corticosteroids Free radical scavengers Parasympatholytics, long-acting Phosphodiesterase inhibitors Surfactant 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rees J.β 2 Agonists and asthma. BMJ 1991;302:1166–7.PubMedGoogle Scholar
  2. 2.
    Van Schayck CP. Treatment of asthma and chronic bronchitis in patients from general practice [dissertation]. Nijmegen: Univ of Nijmegen, 1990.Google Scholar
  3. 3.
    Bown W. Warning letter links asthma death to drugs. New Scientist 1991;27 July.Google Scholar
  4. 4.
    Page CP. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanisms byβ 2-agonists. Lancet 1991;337:717–9.PubMedGoogle Scholar
  5. 5.
    Lofdahl CG. Basic pharmacology of new long-acting sympathomimetics. Lung 1990;168 Suppl:18–21.PubMedGoogle Scholar
  6. 6.
    Johnson M. The pharmacology of salmeterol. Lung 1990;168 Suppl:115–9.PubMedGoogle Scholar
  7. 7.
    Schroeckenstein DC, Bush RK, Chervinsky P, Busse WW. Twelve hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J Allergy Clin Immunol 1988;82:115–9.PubMedGoogle Scholar
  8. 8.
    Ali NJ, Capewell S, Ward MJ. Bone turnover during high dose inhaled corticosteroid treatment. Thorax 1991;46:160–4.PubMedGoogle Scholar
  9. 9.
    Harding SM, Daniel MJ. The clinical pharmacology of inhaled fluticasone [abstract]. SEP-SEPCR Symposium; London, 12 Sept 1990.Google Scholar
  10. 10.
    Beume R, Schudt CH, Riedel R, Kilian U. Zardaverine — a new bronchodilator with anti-allergic and antiinflammatory activity? Eur Respir J 1989;2 Suppl 5:3993.Google Scholar
  11. 11.
    Kroegel C. The role of eosinophils in asthma. Lung 1990;168 Suppl:5–17.PubMedGoogle Scholar
  12. 12.
    Kurihara K, Wardlaw AJ, Moqbel R, Kay AB. Inhibition of platelet activating fator, PAF-induced chemotaxis and PAF-binding to human eosinophils and neutrophils by a specific ginkgolide-derived PAF antagonist BN 52021. J Allergy Clin Immunol 1989;83:82–90.Google Scholar
  13. 13.
    Doelman CJA, Bast A. Oxygen radicals in lung pathology. Free Radical Biol Med 1990;9:381–400.Google Scholar
  14. 14.
    Thomas DA, Myers MA, Wiecert B, Schreier H, Gonzales Rothi RJ. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 1991;99:1269–70.Google Scholar
  15. 15.
    Carell RW. The molecular structure and pathology of alpha 1 antitrypsin. Lung 1990;169 Suppl:530–4.Google Scholar
  16. 16.
    Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1 antitrypsin deficiency by the aerosol route. Lung 1990;169 Suppl:565–8.Google Scholar
  17. 17.
    McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1 antitrypsin treatment for cystic fibrosis. Lancet 1991;337:392–4.PubMedGoogle Scholar
  18. 18.
    Schafer KP, Voss T, Melchers K, Eistetter H. Lung surfactant: a biotechnological challenge. Lung 1990;168 Suppl:851–9.PubMedGoogle Scholar
  19. 19.
    Speer CP, Harms K, Herting E, et al. Early versus late surfactant replacement therapy in severe respiratory distress syndrome. Lung 1990;168 Suppl:870–6.PubMedGoogle Scholar
  20. 20.
    Seeger W, Pison U, Buchhorn R, et al. Surfactant abonormalities and adult respiratory failure. Lung 1990;168 Suppl:891–902.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • A. Van der Kuy
    • 1
  1. 1.Hospital Pharmacy Midden-BrabantLA Tilburgthe Netherlands

Personalised recommendations